The early clinical data from the randomized Phase 2 trial is promising but preliminary — watch for additional data expected in early 2027. The paid named-patient program in Brazil could provide non-dilutive revenue, but the company's cash runway of ~4 quarters at current burn rate means a capital raise is likely within the next 12 months. Monitor for U.S. site activations and any partnership or financing announcements.
Price Chart
Executive Summary
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with cash burn slowing to $8.8M from $9.5M. The key catalyst is the randomized Phase 2 trial of agenT-797 in acute lung injury showing early positive Day 28 signals, plus the first paid named-patient access program in Brazil establishing a potential revenue stream. The stock has historically shown strong positive drift at T+20 (80% win rate, +7.66% avg) on prior filings, but this is a pre-revenue clinical-stage biotech with only $8.8M cash — the clinical data is early and the financials show continued losses, making the risk/reward binary on upcoming data.
Key Financial Metrics
Key Facts
- Q2 2026 net loss $3.1M ($0.62/share) vs $4.2M ($1.06/share) in Q2 2025
- Cash and equivalents $8.8M as of June 30, 2026, down from $9.5M at March 31, 2026
- First patients in randomized Phase 2 trial C-1300-02 alive at Day 28 with improved oxygenation and reduced inflammatory markers
- Launched paid named-patient access program in Brazil for agenT-797, potentially generating program revenue
- No major serious adverse events attributed to agenT-797 in initial patients
- EPS of $-0.57 beat consensus estimate of $-0.60 by 5.0%
Financial Impact
Net loss improved 26% YoY to $3.1M; cash burn of $2.1M in Q2 2026; cash runway of ~4 quarters at current burn rate
Risk Factors
- Pre-revenue clinical-stage biotech with only $8.8M cash — likely needs financing within 12 months
- Early clinical data from small number of patients in ongoing blinded trial may not be predictive of final results
- Named-patient program revenue is uncertain and not a substitute for clinical trial results or regulatory approval
- Stock has high volatility with 80% T+20 win rate but large drawdowns on negative news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344397 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 13, 2026 7w ago | Press Release | $11.00 $12.00 | ▲ +9.09% | ▲ +10.84% | $12.44 (+13.09%) |
Aug 6, 2026 8w ago | Press Release | $11.00 $11.23 | ▲ +2.09% | ▲ +1.49% | $12.44 (+13.09%) |
May 28, 2026 18w ago | Press Release | $12.20 $11.64 | ▼ −4.59% | ▼ −1.45% | $12.44 (+1.97%) |
May 20, 2026 19w ago | Press Release | $10.72 $12.14 | ▲ +13.25% | ▲ +12.51% | $12.44 (+16.04%) |
May 15, 2026 20w ago | 8-K | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 15, 2026 20w ago | Press Release | $10.72 $12.54 | ▲ +16.93% | ▲ +14.81% | $12.44 (+16.04%) |
May 14, 2026 20w ago | Press Release | $10.51 $12.02 | ▲ +14.37% | ▲ +15.23% | $12.44 (+18.36%) |
May 12, 2026 20w ago | Press Release | $11.41 $12.19 | ▲ +6.84% | ▲ +8.56% | $12.44 (+9.03%) |
May 8, 2026 20w ago | Press Release | $10.95 $11.82 | ▲ +7.95% | ▲ +8.25% | $12.44 (+13.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access